[Study on graft-versus-leukemia effects of donor lymphocyte infusion after nonmyeloablative allogeneic bone marrow transplantation].
To explore the graft-versus-leukemia effects of donor lymphocyte infusion(DLI) after nonmyeloablative allogeneic bone marrow transplantation while attenuating treatment-associated morbidity, mortality and graft-versus-host disease. 615(H-2k) mice were loaded with L615 cells and 3 days later received total body irradiation (TBI) 5 Gy (60 Co gamma-ray) followed by allogeneic bone marrow transplantation (allo-BMT). The allo-grafts consisted of 3 x 10(7) bone marrow cells and 1 x 10(7) spleen cells from BALB/c (H-2d) donor mice. Two days after allo-BMT, the recipient mice were given 200 mg/kg of CTX. Afterwards these recipient mice were infused either donor spleen cells (2 x 10(7)) on d14 and d21 or hydrocortison (HC) and cyclosporine A (CsA) treated donor spleen cells (5 x 10(7)) on d14 post-BMT. Survival time of mice received DLI on d21 and pretreated DLI on d14 post-BMT was longer than that of control group and d14 DLI group(P < 0.01) and without severe graft-versus-host disease. Donor lymphocyte infusion after nonmyeloablative bone marrow transplantation could reduce transplantation-associated morbidity and mortality while strengthening graft-versus-leukemia effects.